Aeterna Zentaris Mails Management Information Circular in Connection with Annual Meeting of Shareholders

CHARLESTON, S.C.--()--Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”) today announced that it has mailed a Notice of Meeting and Management Information Circular (the “Meeting Materials”) to the shareholders of record as of March 20, 2017 in connection with its Annual Meeting of shareholders (the “Meeting”) to be held at the offices of Norton Rose Fulbright Canada, 1 Place Ville-Marie, Suite 2500, in Montreal, Canada on Tuesday, May 9, 2017 at 10:00 a.m. (Eastern Time). The Meeting Materials can be found at or on the Company’s SEDAR profile at


The cut-off time for voting is 5:00 p.m. (Eastern Time) on May 5, 2017.

Registered shareholders (those who hold Aeterna Zentaris shares in their name and represented by a physical certificate) may vote by mail, internet, telephone or in person at the Meeting. In the interest of time, shareholders are encouraged to vote via the internet or by telephone using the control number located on their proxy as follows:

  • Internet: Go to the website and follow the instructions on the screen.
  • Telephone: Voting by proxy using the telephone is only available to shareholders located in Canada and the United States. Call 1-866-732-VOTE (8683) toll-free in Canada and 1-312-588-4290 toll-free in the United States from a touchtone telephone and follow the instructions provided.

Beneficial shareholders (those who hold Aeterna Zentaris shares through a bank, broker or other intermediary) will have different voting instructions provided to them and should follow the instructions found on their voting instruction form.

The Board of Aeterna Zentaris UNANIMOUSLY recommends that shareholders vote IN FAVOUR of all the proposed resolutions.

Your vote is important regardless of how many shares you own. The Company encourages shareholders to read the Meeting Materials in detail.

Shareholders who have questions or have not received their proxy or voting instruction form may contact Aeterna Zentaris’ Proxy Solicitation Agent:

Laurel Hill Advisory Group

Toll free: 1-877-452-7184 or 416-304-0211


About Aeterna Zentaris

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We recently completed Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition of licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in non-U.S. territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit


Aeterna Zentaris Inc.
Philip A. Theodore, 843-900-3223
Senior Vice President

Release Summary

Aeterna Zentaris Mails Information Circular in Connection with Annual Meeting



Aeterna Zentaris Inc.
Philip A. Theodore, 843-900-3223
Senior Vice President